sc 51089 has been researched along with amyloid beta-peptides in 1 studies
| Studies (sc 51089) | Trials (sc 51089) | Recent Studies (post-2010) (sc 51089) | Studies (amyloid beta-peptides) | Trials (amyloid beta-peptides) | Recent Studies (post-2010) (amyloid beta-peptides) |
|---|---|---|---|---|---|
| 41 | 1 | 19 | 3,257 | 48 | 1,626 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keene, CD; Li, X; Montine, KS; Montine, TJ; Rose, SE | 1 |
1 review(s) available for sc 51089 and amyloid beta-peptides
| Article | Year |
|---|---|
Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid β neurotoxicity in vitro.
Topics: Amyloid beta-Peptides; Animals; Blotting, Western; Calcium Channel Blockers; Cell Line, Tumor; Cells, Cultured; Coloring Agents; Dinoprostone; Humans; Hydrazines; Mice; Mice, Inbred C57BL; Neurons; Neurotoxicity Syndromes; Nimodipine; Oxazepines; Peptide Fragments; Prostaglandin Antagonists; Receptors, Prostaglandin E, EP1 Subtype; Tetrazolium Salts; Thiazoles | 2013 |